Biovex Limited
Records under this name other than patents Biovex Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,223,593 | Herpes Virus Strains for Gene Therapy Term ended Ended no later than Oct 28, 2026 · Medium confidence | Term ended | Ended no later than Oct 28, 2026 | Medium confidence |
| US 8,679,830 | Viral Vectors Term ended Ended no later than Jan 4, 2026 · Medium confidence | Term ended | Ended no later than Jan 4, 2026 | Medium confidence |
| US 7,981,669 | Viral Vectors Term ended Term ended Jul 26, 2024 · High confidence | Term ended | Term ended Jul 26, 2024 | High confidence |
| US 8,277,818 | Herpes virus strains for gene therapy Term ended Term ended Aug 19, 2022 · USPTO record | Term ended | Term ended Aug 19, 2022 | USPTO record |
| US 7,063,835 | Virus Strains Term ended Term ended Jan 22, 2021 · High confidence | Term ended | Term ended Jan 22, 2021 | High confidence |
| US 7,537,924 | Virus Strains Term ended Ended no later than Jan 22, 2021 · Medium confidence | Term ended | Ended no later than Jan 22, 2021 | Medium confidence |
| US 8,680,068 | Herpes virus strains Term ended Ended no later than Jan 22, 2021 · USPTO record | Term ended | Ended no later than Jan 22, 2021 | USPTO record |
| US 10,301,600 | Virus strains Term ended Ended no later than Jan 22, 2021 · USPTO record | Term ended | Ended no later than Jan 22, 2021 | USPTO record |
| US 6,821,753 | Replication Incompetent Herpes Viruses for Use in Gene Therapy Term ended Term ended Dec 22, 2020 · High confidence | Term ended | Term ended Dec 22, 2020 | High confidence |
| US 6,713,067 | Herpes Viruses for Immune Modulation Term ended Term ended Aug 19, 2019 · High confidence | Term ended | Term ended Aug 19, 2019 | High confidence |